Head and neck cancer is a broad term for several types of cancers that include the mouth (oral cavity), throat (pharynx), voice box (larynx), sinuses and nose cavity, and salivary glands. Head and ...

Merck & Co.’s Keytruda has become the first immunotherapy approved by the FDA to be used around surgery to treat resectable locally advanced head and neck cancer. But the breakthrough approval comes ...

Patients with locally advanced head and neck cancer who received the immune checkpoint inhibitor pembrolizumab before, during and after standard-of-care surgery had longer event-free survival without ...

Imagine being armed with precautionary measures to fight a disease – like being vaccinated before the flu season arrives. What if we could have a similar kind of preparedness for a dangerous disease ...

A novel therapy called amivantamab has shown early signs of effectiveness in treating advanced head and neck cancer, offering hope for patients with limited options.The drug targets two cancer growth ...

Evorpacept and Keytruda combination failed to meet primary endpoints in ASPEN-03 and ASPEN-04 trials for advanced HNSCC. The combination did not improve objective response rates compared to historical ...

Patients with locally advanced head and neck cancer who received the immune checkpoint inhibitor pembrolizumab before, during and after standard-of-care surgery had longer event-free survival without ...

CHICAGO – The postoperative addition of nivolumab (Opdivo) to chemoradiotherapy (CRT) extended disease-free survival (DFS) in certain patients with locally advanced head and neck squamous cell ...

Akeso, Inc. (($HK:9926)) announced an update on their ongoing clinical study. Akeso, Inc. is conducting a Phase 3 clinical study titled A ...

Please provide your email address to receive an email when new articles are posted on . Adding perioperative pembrolizumab to standard of care significantly improved EFS for patients with advanced ...

In a phase 3 trial, the addition of xevinapant to chemoradiotherapy resulted in worse event-free and overall survival and more serious adverse events in patients with unresected locally advanced head ...